Sorafenib has the potential to block a variety of oncogenic Ras and Raf mutations, including the BRAF V600E mutant, which is linked to tumor angiogenesis and invasion, as well as the silencing of tumor suppressor genes in a spectrum of cancer types and also inhibits VEGF receptors, platelet-derived growth factor receptor family proteins (PDGFR and Kit), and FMS-related tyrosine kinase 3 (FLT-3) (91), as well as the oncogenic RET kinase (92) and the degradation of the anti-apoptotic myeloid cell leukemia 1 (Mcl-1) protein (93). Here, FLT3 is linked to cancer.